Second‐line axicabtagene ciloleucel in large B‐cell lymphoma ineligible for transplantation: ALYCANTE final analysis
Open Access
- 22 September 2026
- journal article
- letter
- Published by Wiley in HemaSphere
- Vol. 10 (9) , e70472
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphomaBlood Advances, 2026
- Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT studyBlood Advances, 2025
- Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialNature Medicine, 2023
- Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaNew England Journal of Medicine, 2023
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaNew England Journal of Medicine, 2022
- Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantationLeukemia & Lymphoma, 2021
- Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2021
- Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured reviewLeukemia & Lymphoma, 2019